Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Stock Information for Cabaletta Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cabaletta Bio Inc.

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Cabaletta Bio Announces Pricing of Public Offering of Securities

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.